The design and delivery of a PKA inhibitory polypeptide to treat SCA1

Journal of Neurochemistry

Volumn 131, Issue 1, 2014, Pages 101-114

  Hearst, Scoty M ^a,b   Shao, Qingmei ^a   Lopez, Mariper ^a   Raucher, Drazen ^b   Vig, Parminder J S ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

ataxin 1 phosphorylation; intranasal peptide delivery; neurodegeneration; PKA inhibitory peptide; Purkinje cell; spinocerebellar ataxia 1

Indexed keywords

ATAXIN 1; CELL PENETRATING PEPTIDE; CELL PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ELASTIN; PROTEIN S100B; SERINE; SYNB1 ELASTIN LIKE POLYPEPTIDE; UNCLASSIFIED DRUG; PEPTIDE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL STRUCTURE; CEREBELLUM; CONTROLLED STUDY; DENDRITIC SPINE; DRUG DELIVERY SYSTEM; DRUG DESIGN; ENZYME INHIBITION; MOUSE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PURKINJE CELL; SPINOCEREBELLAR DEGENERATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MOLECULAR GENETICS; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PROCEDURES; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AMINO ACID SEQUENCE; ANIMALS; CEREBELLUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HEK293 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; ORGAN CULTURE TECHNIQUES; PEPTIDES; PROTEIN KINASE INHIBITORS; SPINOCEREBELLAR ATAXIAS; TREATMENT OUTCOME;

EID: 84921725605     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12782     Document Type: Article

References (50)

1. Adami C., Bianchi R., Pula G., and, Donato R., (2004) S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim. Biophys. Acta 1742, 169-177.
2. Allen T. M., (1998) Liposomal drug formulation: rationale for development and what we can expect in the future. Drugs 56, 747-756.
3. Bidwell G. L., 3rd, and, Raucher D., (2005) Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther. 4, 1076-1085.
4. Bidwell G. L., 3rd, and, Raucher D., (2010) Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv. Drug Deliv. Rev. 62, 1486-1496.
5. Bidwell G. L., 3rd, Davis A. N., and, Raucher D., (2009) Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J. Control. Release 135, 2-10.
6. Bidwell G. L. 3rd, Whittom A. A., Thomas E., Lyons D., Hebert M. D., and, Raucher D., (2010) A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 31, 834-841.
7. Bidwell G. L., 3rd, Perkins E., and, Raucher D., (2012) A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 319, 136-143.
8. Bidwell G. L., 3rd, Perkins E., Hughes J., Khan M., James J. R., and, Raucher D., (2013) Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE 8, e55104.
9. Burright E. N., Clark H. B., Servadio A., Matilla T., Feddersen R. M., Yunis W. S., Duvick L. A., Zoghbi H. Y., and, Orr H. T., (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948.
10. Campbell C., Morimoto B. H., Nenciu D., and, Fox A. W., (2012) Drug development of intranasally delivered peptides. Ther. Deliv. 3, 557-568.
11. 2+ as examined by NMR and X-ray crystallography. J. Mol. Biol. 396, 1227-1243.
12. Chen H. K., Fernandez-Funez P., Acevedo S. F., et al,. (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113, 457-468.
13. Collins S. P., and, Uhler M. D., (1997) Characterization of PKIgamma, a novel isoform of the protein kinase inhibitor of cAMP-dependent protein kinase. J. Biol. Chem. 272, 18169-18178.
14. Demaille J. G., Peters K. A., and, Fischer E. H., (1977) Isolation and properties of the rabbit skeletal muscle protein inhibitor of adenosine 3',5'-monophosphate dependent protein kinases. Biochemistry 16, 3080-3086.
15. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., Tubaro C., and, Giambanco I., (2009) S100B's double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793, 1008-1022.
16. Dreher M. R., Liu W., Michelich C. R., Dewhirst M. W., and, Chilkoti A., (2007) Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res. 67, 4418-4424.
17. Emamian E. S., Kaytor M. D., Duvick L. A., Zu T., Tousey S. K., Zoghbi H. Y., Clark H. B., and, Orr H. T., (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38, 375-387.
18. Glass D. B., Feller M. J., Levin L. R., and, Walsh D. A., (1992) Structural basis for the low affinities of yeast cAMP-dependent and mammalian cGMP-dependent protein kinases for protein kinase inhibitor peptides. Biochemistry 31, 1728-1734.
19. Hanson L. R., and, Frey W. H. 2nd, (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 9 Suppl 3, S5.
20. Hearst S. M., Lopez M. E., Shao Q., Liu Y., and, Vig P. J., (2010) Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation. J. Neurochem. 114, 706-716.
21. Hearst S. M., Walker L. R., Shao Q., Lopez M., Raucher D., and, Vig P. J., (2011) The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration. Neuroscience 197, 369-380.
22. Jorgensen N. D., Andresen J. M., Lagalwar S., et al,. (2009) Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 110, 675-686.
23. Kissel M., Peschke P., Subr V., Ulbrich K., Schuhmacher J., Debus J., and, Friedrich E., (2001) Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors. PDA J. Pharm. Sci. Technol. 55, 191-201.
24. Koeppen A. H., (2005) The pathogenesis of spinocerebellar ataxia. Cerebellum 4, 62-73.
25. Liu W., Dreher M. R., Furgeson D. Y., Peixoto K. V., Yuan H., Zalutsky M. R., and, Chilkoti A., (2006) Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J. Control. Release 116, 170-178.
26. 2+ binding protein S100B: role in D2 receptor function. Mol. Pharmacol. 74, 371-378.
27. Massodi I., Thomas E., and, Raucher D., (2009) Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules 14, 1999-2015.
28. Matilla-Duenas A., Goold R., and, Giunti P, (2008) Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 7, 106-114.
29. McPherson D. T., Morrow C., Minehan D. S., Wu J., Hunter E., and, Urry D. W., (1992) Production and purification of a recombinant elastomeric polypeptide, G-(VPGVG)19-VPGV, from Escherichia coli. Biotechnol. Prog. 8, 347-352.
30. Meyer D. E., and, Chilkoti A., (1999) Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat. Biotechnol. 17, 1112-1115.
31. Moktan S., Ryppa C., Kratz F., and, Raucher D., (2012) A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest. New Drugs 30, 236-248.
32. Neve K. A., Seamans J. K., and, Trantham-Davidson H., (2004) Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165-205.
33. Olsen S. R., and, Uhler M. D., (1991) Isolation and characterization of cDNA clones for an inhibitor protein of cAMP-dependent protein kinase. J. Biol. Chem. 266, 11158-11162.
34. Ong S. R., Trabbic-Carlson K. A., Nettles D. L., Lim D. W., Chilkoti A., and, Setton L. A., (2006) Epitope tagging for tracking elastin-like polypeptides. Biomaterials 27, 1930-1935.
35. Orr H. T., and, Zoghbi H. Y., (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621.
36. Parfitt D. A., Michael G. J., Vermeulen E. G., Prodromou N. V., Webb T. R., Gallo J. M., Cheetham M. E., Nicoll W. S., Blatch G. L., and, Chapple J. P., (2009) The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1. Hum. Mol. Genet. 18, 1556-1565.
37. Renner D. B., Svitak A. L., Gallus N. J., Ericson M. E., Frey W. H., 2nd, and, Hanson L. R., (2012) Intranasal delivery of insulin via the olfactory nerve pathway. J. Pharm. Pharmacol. 64, 1709-1714.
38. Rousselle C., Clair P., Lefauconnier J. M., Kaczorek M., Scherrmann J. M., and, Temsamani J., (2000) New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57, 679-686.
39. Sarantseva S. V., Bol'shakova O. I., Timoshenko S. I., Kolobov A. A., Vitek M. P., and, Shvartsman A. L., (2009) Protein transduction domain peptide mediates delivery to the brain via the blood-brain barrier in Drosophila. Biomed. Khim. 55, 41-49.
40. Seasholtz A. F., Gamm D. M., Ballestero R. P., Scarpetta M. A., and, Uhler M. D., (1995) Differential expression of mRNAs for protein kinase inhibitor isoforms in mouse brain. Proc. Natl Acad. Sci. USA 92, 1734-1738.
41. Skinner P. J., Vierra-Green C. A., Clark H. B., Zoghbi H. Y., and, Orr H. T., (2001) Altered trafficking of membrane proteins in purkinje cells of SCA1 transgenic mice. Am. J. Pathol. 159, 905-913.
42. Sorci G., Bianchi R., Riuzzi F., Tubaro C., Arcuri C., Giambanco I., and, Donato R., (2010) S100B Protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc. Psychiatry Neurol. doi: 10.1155/2010/656481. [epub ahead of print].
43. Southam D. S., Dolovich M., O'Byrne P. M., and, Inman M. D., (2002) Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L833-L839.
44. Urry D. W., (1992) Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog. Biophys. Mol. Biol. 57, 23-57.
45. Van Patten S. M., Howard P., Walsh D. A., and, Maurer R. A., (1992) The alpha- and beta-isoforms of the inhibitor protein of the 3',5'-cyclic adenosine monophosphate-dependent protein kinase: characteristics and tissue- and developmental-specific expression. Mol. Endocrinol. 6, 2114-2122.
46. Vig P. J., Lopez M. E., Wei J., D'Souza D. R., Subramony S., Henegar J., and, Fratkin J. D., (2006a) Glial S100B positive vacuoles in purkinje cells: earliest morphological abnormality in SCA1 transgenic mice. J. Neurol. Sci. Turk. 23, 166-174.
47. Vig P. J., Subramony S. H., D'Souza D. R., Wei J., and, Lopez M. E., (2006b) Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res. Bull. 69, 573-579.
48. Vig P. J., Shao Q., Subramony S. H., Lopez M. E., and, Safaya E., (2009) Bergmann glial S100B activates myo-inositol monophosphatase 1 and Co-localizes to purkinje cell vacuoles in SCA1 transgenic mice. Cerebellum 8, 231-244.
49. Vig P. J., Hearst S., Shao Q., Lopez M. E., Murphy H. A., 2nd, and, Safaya E., (2011) Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy. Cerebellum 10, 254-266.
50. Zheng L., Yu L., Tu Q., Zhang M., He H., Chen W., Gao J., Yu J., Wu Q., and, Zhao S., (2000) Cloning and mapping of human PKIB and PKIG, and comparison of tissue expression patterns of three members of the protein kinase inhibitor family, including PKIA. Biochem. J. 349, 403-407.